Table 3 Multivariate analyses by Cox-proportional hazards model
Model 1 | Model 2 | Model 3 | ||||||
|---|---|---|---|---|---|---|---|---|
OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |||
Age | 1.04 (0.99–1.09) | 0.12 | Age | 1.04 (0.99–1.09) | 0.15 | Age | 1.04 (0.99–1.09) | 0.12 |
Gender (Women) | 1.41 (0.33–5.97) | 0.64 | Gender (Women) | 1.41 (0.32–6.31) | 0.65 | Gender (Women) | 1.43 (0.34–6.11) | 0.63 |
SGLT2i, yes | 7.59 (1.56–36.90) | 0.01 | SGLT2i, yes | 7.59 (1.55–37.13) | 0.01 | SGLT2i, yes | 7.13 (1.44–35.30) | 0.02 |
Log BMI | 1.01 (0.03–38.34) | 0.99 | HFrEF | 1.37 (0.45–4.16) | 0.58 | |||
Model 4 | Model 5 | Model 6 | ||||||
|---|---|---|---|---|---|---|---|---|
OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |||
Age | 1.04 (0.99–1.09) | 0.12 | Age | 1.05 (0.99–1.11) | 0.08 | Age | 1.10 (0.99–1.10) | 0.13 |
Gender (Women) | 1.36 (0.28–6.48) | 0.70 | Gender (Women) | 1.52 (0.35–6.54) | 0.58 | Gender (Women) | 1.48 (0.33–6.62) | 0.61 |
SGLT2i, yes | 7.52 (1.54–36.79) | 0.01 | SGLT2i, yes | 8.10 (0.35–6.54) | 0.01 | SGLT2i, yes | 7.70 (1.58–37.59) | 0.01 |
Ischemic, yes | 0.92 (0.27–3.11) | 0.90 | Log eGFRcys | 2.26 (0.65–7.87) | 0.20 | Log NT-proBNP | 0.94 (0.59–1.48) | 0.79 |
Model 7 | Model 8 | Model 8 | ||||||
|---|---|---|---|---|---|---|---|---|
OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |||
Age | 1.06 (1.00-1.16) | 0.04 | Age | 1.05 (0.99–1.11) | 0.06 | Age | 1.04 (0.99–1.08) | 0.15 |
Gender (Women) | 2.36 (0.48–11.44) | 0.27 | Gender (Women) | 1.85 (0.41–8.46) | 0.43 | Gender (Women) | 1.42 (0.34-6.00) | 0.63 |
SGLT2i, yes | 6.32 (1.25–31.8) | 0.03 | SGLT2i, yes | 7.39 (1.49–36.65) | 0.01 | SGLT2i, yes | 8.54 (1.71–42.68) | < 0.01 |
Albumin | 4.82 (1.06–21.97) | 0.04 | Hemoglobin | 1.23 (0.90–1.11) | 0.20 | HbA1c | 0.75 (0.42–1.35) | 0.34 |